ABO血型主要不合供者外周血干细胞单采中COM.TEC血细胞分离机的应用

背景:异基因外周血造血干细胞移植大约1/3是在ABO血型不合的供受者之间进行的.目的:探讨ABO血型主要不合供者外周血造血干细胞在不去除红细胞情况下应用COM.TEC血细胞分离机直接回输给受者的可行性.方法:27例HLA全相合同胞供者皮下注射粒细胞集落刺激因子5 μg/(kg?d),连续5 d干细胞动员,于第5天开始应用COM.TEC血细胞分离机进行外周血造血干细胞单采,每次总处理血量为3.0~3.5个供者全身血量.ABO相合供者按常规方法进行单采,主要不合供者采取动态调整白膜收集量和保持稳定充足的血流量以减少红细胞污染.结果与结论:27例供者中ABO主要不合供者11例,相合供者16例.主要不合组产品体积及红细胞内含量均显著低于相合组(P < 0.05),回输给受者均未出现急性溶血反应;2组单个核细胞及CD34+细胞计数差异无显著性意义(P > 0.05),受者均获造血重建,中性粒细胞及血小板重建时间相似(P > 0.05).提示应用COM.TEC血细胞分离机进行ABO主要不合供者外周血造血干细胞单采,可以保持稳定充足的血流量情况下通过动态调整白膜收集量参数,在不影响采集产品产量和质量的同时显著减少红细胞的污染,预防回输后受者的急性溶血反应.     

ABO血型不合供者外周血造血干细胞的采集

目的研究ABO血型不合供者外周血造血干细胞的采集方法,探讨不去除红细胞和/或血浆进行造血干细胞移植的安全性。方法 29例异基因外周血干细胞移植供者与受者HLA配型为全相合或1～3位点不合,其中ABO主要不合13例,次要不合7例,ABO血型相合9例。采用CS-3000Plus血细胞分离机的干细胞采集程序对ABO血型不合供者的外周血造血干细胞进行采集,不去除红细胞和/或血浆,直接回输给受者。结果 ABO血型主要不合、次要不合及血型相合的供者每次采集的外周血干细胞(PBSC)产品终体积为(59.11±1.19)ml,单个核细胞(MNC)采集物、MNC比例、CD34+细胞、RBC含量三组间的差异无统计学意义。结论应用CS-3000Plus血细胞分离机采集ABO血型不合供者外周血造血干细胞,不仅对供者安全,而且采集产品中造血干细胞浓度较高,血型不合的红细胞污染较少,不需要去除红细胞和血浆,可安全地用于ABO血型不合的受者。     

ABO血型不合供者外周血造血干细胞的采集及移植效果研究

目的探讨应用CS-3000 Plus血细胞分离机采集ABO血型不合供者外周血造血干细胞的效率及不去除红细胞和/或血浆进行异基因外周血造血干细胞移植(PBSCT)的安全性。方法经G-CSF 5μg/(kg.d)动员的异基因外周血干细胞供者33名,应用CS-3000 Plus血细胞分离机的干细胞采集程序于动员后d 5采集,其中ABO血型主要不合12名,次要不合8名以及ABO血型相合13名。根据供者外周血的红细胞压积(Hct)和单个核细胞(MNC)计数,对分离机参数作相应调整。输注前从产品袋中留取干细胞,检测有核细胞数、MNC比例、CD34+细胞数、红细胞、血浆含量。单次处理循环血量(9 986±2 489)ml,抗凝剂用量(971±162)ml。供者采集前注射10%葡萄糖酸钙,以预防低钙反应。观察PBSC输注后受者的生命体征、尿液颜色及是否有溶血相关不良反应等。结果ABO血型主要不合组、次要不合组与ABO血型相合组采集物中的有核细胞数、CD34+细胞数、MNC比例无统计学差异(P>0.05),3组供者每次采集的PBSC产品终体积近60 ml,ABO主要不合组采集物中混入红细胞为(3.67—10.25)×1010/袋,ABO次要不合组采集物中血浆量为22—38 ml,不去除红细胞及血浆,直接回输给受者,均未出现溶血反应,所有患者造血功能均获得重建。结论应用CS-3000 Plus血细胞分离机采集ABO血型不合供者的外周血干细胞,通过调整分离机参数,减少ABO血型不合红细胞的混入,可以获得足够的干细胞数量并安全用于移植。     

ABO血型不合的异基因造血干细胞采集及移植效果研究

本研究评价COBE Spectra血细胞分离机按干细胞采集程序采集HLA配型相合、ABO血型不合供者外周血造血干细胞的效能,观察未去除红细胞和(或)血浆进行异基因外周血干细胞移植的效果。应用COBE Spectra血细胞分离机的自动干细胞采集程序采集28例异基因供者外周血干细胞,并选用同期ABO血型相合15例作对照。检测采集物有核细胞(NC)数、单个核细胞(MNC)比例及CD34+细胞计数,观察造血功能重建情况和转变为供者血型所需要的时间。结果表明,ABO血型不合和相合组采集物中的NC、CD34+细胞数、MNC比例无统计学差异(p>0.05)。ABO血型不合组和相合组中性粒细胞和血小板恢复的时间无统计学差异(p>0.05)。14例ABO血型主要不合患者,红系造血明显延迟,ABO血型不合组28名患者于移植后35-193天血型成功转变为供者型,和ABO血型相合组相比均有统计学差异(p<0.01)。结论:ABO血型不合不是异基因造血干细胞移植的障碍,主要不合可能是红系造血明显延迟的主要原因。     

应用CS-3000 Plus血细胞分离机采集血型不合供者的外周血干细胞的临床研究

[目的]探讨应用CS-3000 Plus血细胞分离机采集ABO及Rh血型不合的供者外周血干细胞(PBSC)的得率及不去除红细胞或血浆用于异基因外周血干细胞移植的可行性.[方法]采用CS-3000 Plus血细胞分离机的自动干细胞采集程序对14例异基因外周血干细胞供者进行采集,其中ABO血型主要不合5例,次要不合6例,主要次要均不合2例,Rh血型主要不合1例.供者循环收集的细胞成分按供者外周血的红细胞比容(HCT)和单个核细胞(MNC)计数作相应调整.输注前从产品袋中留取标本检查有核细胞计数、MNC比例、CD34 细胞计数和台盼蓝拒染率.回输时对受者采取使用糖皮质激素、水化、碱化、利尿等保护措施.[结果]供者均经2～3次采集收集到足够的有核细胞直接回输给受者.共采集PBSC 30次,平均每次获得有核细胞5.65×1010,单个核细胞占96%～98%.CD34 细胞数平均为6.52×106/kg,细胞拒染率均为100%.ABO血型主要不合、主要、次要均不合及Rh主要血型不合的供者每次采集的PBSC产品终体积均为50 ml,产品中含压积红细胞3～7 ml,ABO血型次要不合供者每次采集的PBSC产品中含血浆15～25 ml,不去除红细胞及血浆,直接回输给受者,无一例出现溶血性输血反应,造血均获得重建.[结论]采用CS-3000Plus血细胞分离机,通过调整参数采集血型不合供者的外周血干细胞,减少血型不合的红细胞,可以获得足够的干细胞数量并安全用于移植.     

应用血细胞分离机采集ABO血型不合供者的外周血干细胞

为了探索应用血细胞分离机采集ABO血型主要和(或)次要不合的供者外周血造血干细胞的得率及不去除红细胞或血浆用于干细胞移植的可行性,采用CobeSpectra(Version6.1)血细胞分离机的自动干细胞采集程序对9例异基因外周血造血干细胞供者进行采集,其中ABO血型主要不合4例,次要不合2例,主要次要均不合3例。对ABO血型主要不合及主要、次要均不合的供者每循环收集的细胞成分和血浆的量分别作相应调整。输注前从产品袋中留取标本检查有核细胞计数、单个核细胞比例、CD34 细胞计数和细胞的成活率(台盼蓝拒染率)。输入时对受者采取一系列保护肾功能的措施。液体总量控制在4000毫升/日。结果显示:除1例因供者体重远大于受者经1次采集即可满足移植所需细胞量外,其余供者均经2次采集收集到足够的有核细胞直接回输给受者或冰冻保存备用。共采集PBSC17次,平均每次获得有核细胞3.77×1010个,单个核细胞占97%-99%。CD34 细胞数平均为8.62×106/kg,细胞拒染率均为100%。ABO血型主要不合及主要、次要均不合的供者每次采集的PBSC产品中含压积红细胞8-10ml,ABO血型次要不合供者每次采集的PBSC产品中含血浆80-120ml,不去除红细胞及血浆,直接回输给受者。无1例出现溶血性输血反应,造血功能均获得重建。结论:采用CobeSpectra血细     

ABO血型不合异基因造血干细胞移植对红系造血恢复的影响

本研究探讨ABO血型不合异基因造血干细胞移植对红系造血的影响。对16例ABO血型不合的造血干移植患者的ABO血型,IgM和IgG抗体进行监测。结果显示,16例ABO血型不合的造血干细胞移植患者均恢复造血功能,与ABO血型相合组比较,ABO血型不合组在粒细胞植活时间、血小板植活时间无差异,但红系重建时间明显延长;ABO主侧不合与双侧不合受者抗供者凝集素消失时间与红系恢复时间有相关性。结论 :ABO血型不合的异基因造血干细胞移植会导致红系造血迟缓。移植前用供型血浆置换法或输注供者红细胞来中和受者体内抗供者红细胞的凝集素能缩短红细胞植入时间,减少红细胞的输注。     

ABO血型不合外周血造血干细胞移植10例

背景：ABO血型不合供受者之间进行外周血造血干细胞移植,面临受者血型的转变、移植后输血的选择等问题.目的：观察ABO血型不合外周血造血干细胞移植治疗血液病的临床疗效和近远期并发症.方法：回顾性分析了2005/2008武警总医院收治的10例ABO血型不合异基因外周血同胞供者造血干细胞移植患者的资料.总结植入效果,血型转变,移植物抗宿主病以及不良反应.结果与结论：9例患者恢复造血功能,血型转变为完全供者型,1例患者白细胞血小板恢复,但红细胞植入延迟.所有患者在输注移植物时未出现短暂的血红蛋白尿,无严重急性溶血和迟发型溶血的发生,1例出现严重的移植物抗宿主病.可见ABO血型不合外周血造血干细胞移植对移植疗效无明显影响,红细胞植入延迟的预防和处理十分重要.     

ABO血型不合异基因造血干细胞移植的护理

目的:探讨HLA相合而ABO血型不合异基因造血干血胞移植中,为了避免ABO血型不合引起的溶血反应,对骨髓、外周血或受者的处理和移植后输血的选择问题。方法:对本科23例ABO血型不合HLA相合的干细胞移植期间,受者及供者造血干细胞的处理情况及护理作回顾性分析和总结。结果:23例ABO血型不合而HLA相合的患者移植后无一例发生溶血反应,也不影响骨髓移植存活率。结论:提高护士对ABO血型不合的造血干细胞移植患者溶血及贫血症状的观察及护理,是护理此类病人的关键。     

ABO血型不合异基因造血干细胞移植治疗恶性血液病

背景:由于移植技术的提高,供受者ABO血型不合已不再是异基因造血干细胞移植的障碍,但是由于宿主血凝素抗体的持续存在,ABO血型不合异基因造血干细胞移植后常出现红细胞系统恢复的延迟.目的:观察ABO血型不合异基因造血干细胞移植患者红细胞系统恢复情况,评价血型不合、人类白细胞抗原配型不相合对造血功能重建的影响.设计:回顾性分析.单位:南京大学医学院附属鼓楼医院血液科.对象:选择2002-05/2007-09在南京大学医学院附属鼓楼医院血液科行ABO血型不合异基因造血干细胞移植的恶性血液患者(受者)14例,男11例,女3例;年龄15～60岁.14例患者中7例供受者人类白细胞抗原配型完全相合.7例供受者人类白细胞抗原配型半相合.纳入同期ABO血型相合的造血干细胞移植患者11例为对照.受者在接受异基凶造血干细胞移植前签署移植同意书,供者为同胞姊妹、胞弟、儿子、母亲,均同意提供用于移植的骨髓.实验经医院伦理委员会批准.方法:①预处理方案:人类白细胞抗原配型全相合组采取马利兰和环磷酰胺为主的方案.人类白细胞抗原配型半不合组采用北京人民医院的GlAC方案.②造血干细胞输注:沉降供者骨髓.取上层有核细胞输给受者.主要观察指标:观察ABO血型不合异基因造血干细胞移植的副反应、并发症及造血重建情况.结果:14例ABO血型不合患者仅1例发生单纯红细胞再生障碍性贫血未进入结果分析.①造血功能重建情况:与对照组比较,ABO血型不合组血红蛋白恢复时间明显延迟(t=2.352,P＜0.05),ABO血型相同与ABO血型不合组中性粒细胞和血小板恢复情况差异无显著性意义(P＞0.05).ABO血型不合的人类白细胞抗原配型半不合造血干细胞组血红蛋白恢复和血型转换时间迟于全相合,但其差异无显著性意义(P＞0.05).②并发症:14例ABO血型不合患者移植后成分输血过程未出现溶血反应,移植后也均未发生迟发性溶血反应.结论:ABO血型不合不影响造血干细胞移植的效果,且较为安全.     

Automated CD14+ monocyte collection with the autoMNC program of the COM.TEC cell separator

BACKGROUND: The standard mononuclear cell (MNC) program of the COM.TEC device (Fresenius HemoCare GmbH) showed excellent collection efficiency of CD14+ monocytes. A major disadvantage was high content of residual cells in MNC harvests, which could influence dendritic cell (DC) culture. STUDY DESIGN AND METHODS: The autoMNC program (COM.TEC) was compared with the standard MNC program (n = 12). Additionally, two cycle volumes (300 mL vs. 450 mL, n = 19) were compared (standard MNC program). Samples were assayed for white blood cells (WBCs), red blood cells (RBCs), granulocytes (PMNs), hematocrit, and platelets (PLTs) on an automated blood cell counter (Sysmex K 4500, TAO Medical). CD14+ cells were analyzed by flow cytometry (FACSCalibur, BD). RESULTS: The autoMNC program produced 1.33 x 10(9) +/- 0.36 x 10(9) CD14+ cells, 5.60 x 10(11) +/- 0.97 x 10(11) PLTs, and 1.43 x 10(11) +/- 0.37 x 10(11) RBCs. Compared to the standard MNC program, significantly higher PLT yields but lower RBC yields and product volume were harvested. Increasing the CV from 300 to 450 mL dropped the product volume, residual PLTs, and RBCs significantly, whereas WBC and monocyte yields did not change. The WBC predonation counts of donors correlated significantly with monocyte yields. CONCLUSIONS: The autoMNC program reduced the buffy coat (BC) volume and RBC yields in products compared to the standard MNC program. Increasing the CV (standard MNC program) reduced residual PLTs, RBCs, and the BC volume of MNC harvests. The donor WBC predonation count was a good predictor for the monocyte yield of products.     

Regeneration of erythropoiesis after related- and unrelated-donor BMT or peripheral blood HPC transplantation: a major ABO mismatch means problems

BACKGROUND: Blood group incompatibility in allogeneic BMT is common but does not appear to affect the outcome in terms of incidence of graft rejection or delayed engraftment. However, major ABO incompatibility may be associated with prolonged erythroid aplasia. STUDY DESIGN AND METHODS: In a retrospective analysis of 286 allogeneic transplant recipients, the prevalence of prolonged erythroid aplasia, including pure RBC aplasia, was determined. RESULTS: Patients receiving major ABO-incompatible grafts showed a significant delay in reticulocyte engraftment (median, 32 days; range, 12-347) from that in patients receiving ABO-identical (20; 10-152) or minor ABO-incompatible (21; 12-47) grafts. Pure RBC aplasia occurred in 7 (3%) of 240 evaluable recipients and was observed only in the major ABO-incompatible group (7/43, 16%). Treatment of pure RBC aplasia consisted of either plasma exchange, which resulted in a response within 16 to 68 days, or immunoadsorption, in which the response occurred between Days 119 and 204 after initiation of treatment. CONCLUSION: Major ABO incompatibility may lead to delayed reticulocyte engraftment, resulting in prolonged transfusion dependency and increased risks of transmission of infection and iron overload. Therefore, therapeutic strategies should be taken into consideration to allow erythroid reconstitution in these patients.     

PK7300全自动血型分析仪测定ABO血型抗体效价的初步研究

目的：探索使用PK7300全自动血型分析仪测定ABO血型抗体效价的方法,探讨献血者血型检测中与ABO血型抗体效价相关的影响因素及注意事项。方法仪器微板法测定抽样标本的ABO血型抗体效价;仪器微板法及手工试管法测定各血型混合血浆的ABO血型抗体效价;统计分析该中心2013年5～7月检测出的ABO血型抗体效价降低的情况。结果A型献血者与B型献血者的ABO血型抗体效价比较,差异无统计学意义（P＞0．05）,O型献血者的ABO血型抗体效价明显高于A型或B型献血者（P＜0．05）;手工试管法的灵敏度明显优于仪器微板法,而手工试管法二的灵敏度又明显优于手工试管法一（P＜0．05）;ABO血型抗体效价降低的A型献血者明显多于B型或O型（均P＜0．01）,ABO血型抗体效价降低的男性献血者明显多于女性（P＜0．01）。结论仪器微板法测定ABO血型抗体效价操作简便、结果判读客观、重复性好,1∶1～1∶80的稀释比例范围能满足绝大多数标本的测定需要,采用梯度稀释有助于减小测定误差;血型、性别、年龄、亚型等因素可能与献血者ABO血型抗体效价降低相关。     

Bone marrow processing on the Haemonetics V50 cell separator

We have processed 27 bone marrow (BM) harvests using the Haemonetics V50 cell separator with a paediatric plasmapheresis set and programmed for lymphocyte collection. The mean starting volume of 843 mL was processed in 6-8 cycles to a buffy coat (BC) with a mean volume of 230 mL. The mean starting mononuclear cell (MNC) count was 1.22 x 10 8/kg recipient weight, and recovery was 92%. Clonogenic potential of the BC was assessed using CFU-GM assays and recovery was measured after cryopreservation or purging. On 4 occasions where major ABO incompatibility existed between donor and recipient, both BM and BC were consecutively diluted in compatible blood and processed twice. This achieved a calculated reduction in donor erythrocytes of 98%. The procedure was efficient and yielded a BC fraction suitable for cryopreservation and purging. Adequate stem-cells were retained as verified by CFU-GM assays and documentation of stable engraftment.     

无偿献血者外周红细胞指标对单采血小板质量的影响

目的：探讨无偿献血者外周红细胞指标对单采血小板质量的影响,并探讨筛选献血者的适宜标准。方法：收集194名无偿献血者的献血前外周红细胞指标（包括红细胞平均体积、平均血红蛋白含量、平均血红蛋白浓度）与单采血小板收集量进行单因素相关分析,并对献血者采集前后的相应指标作配对比较。结果：无偿献血者的采血前外周红细胞平均体积、平均血红蛋白含量、平均血红蛋白浓度均与单采血小板收集量呈负相关关系,且有统计学意义。结论：外周红细胞指标是筛选单采血小板无偿献血者的重要指标。     

ABO血型不合的非清髓异基因外周血干细胞移植

为了探讨ABO血型不合对HLA相合的非清髓异基因外周血干细胞移植(NAST)的影响,回顾分析了15例ABO血型主要不舍,9例次要不合的HLA相合的NAST的临床特点,并选用同期ABO血型相合的NAST作成组比较。结果显示：24例ABO血型不合的NAST受者在输入供者外周血千细胞悬液时无1例发生急性溶血,但有2例发生迟发性溶血。统计学分析表明,ABO血型不合对NAST骨髓植活、血小板恢复、GVHD、疾病复发及无病生存均无影响。在ABO血型主要不合组,红系开始恢复时间明显延迟,其中1例“0”型血受者发生纯红细胞再生障碍,持续5个月。结论：ABO血型不合不是NAST的障碍,仅在ABO血型主要不合时．红系恢复时间延迟。     

Collection of mobilized peripheral blood stem cells from a donor with severe iron deficient anemia

We report a 45-year-old woman with iron deficient anemia (IDA) who underwent a collection of allogeneic peripheral blood stem cells (PBSCs) induced by granulocyte-colony stimulating factor (G-CSF) after a rapid improvement of IDA by iron replacement. Her peripheral red blood cells (RBCs) after iron therapy were composed of two different-sized subpopulations; one consisted of microcytes, which were iron deficient RBCs, and another of normocytes, which were produced after iron replacement. On the first day of PBSC collection, the interface setting was maintained aiming at 2% hematocrit as usual; however, PBSCs could not be collected adequately. Sedimentation of iron deficient, lighter RBCs under centrifugation within a blood cell separator could be similar to that of mononuclear cells, and the lighter RBCs could contaminate the mononuclear cell layer, resulting in the collection of the lighter layers of mononuclear cells than desired. On the second day, we succeeded in obtaining enough PBSCs by collecting heavier layers than those collected on the first day by using a 4% hematocrit and monitoring white blood cell counts of the collection line serially. It should be noted that the lighter RBCs from a donor with a history of IDA could complicate collection of PBSCs.     

Clinical impact of a new automated system employed for peripheral blood stem cell collection

At the moment, PBSC collections can be performed using semi-automated or automated cell separator devices. The automated methods offer the advantages of a decreased working load for dedicated personnel and high standardization of the collection procedure. Herein we report our single institutional experience in 80 PBSC collections employing the new automated COM.TEC Fresenius autoMNC program that provides the ability to predict the total number of CD34(+) cells collected, based on the pre-leukapheresis CD34(+) cell count in peripheral blood. Fourty-eight patients and 21 healthy donors were mobilized with chemotherapy + G-CSF or G-CSF alone, respectively. Eighty leukapheresis collections were performed starting with a CD34(+) cell count in peripheral blood at least of 20/microL. Collection parameters and related side effects were evaluated. The mean CD34(+) cell collection efficiency in patients and donors was 81.8% (sd 27.6) and 95.1% (sd 15.6), respectively. The mean difference between real and predicted CD34(+) cells was +30.2% (sd 92.9) for patients and +4.6% (sd 30.3) for donors. The mean leukapheresis bag volume was 240.7 ml (sd 67.3) and 310.3 ml (sd 86.8) with a mean HCT of 10.9% (sd 34.4) and 9.2% (sd 3.9) for patients and donors, respectively. The automated PBSC collection with the new program COM.TEC Fresenius autoMNC demonstrated a very high CD34(+) cell collection efficiency. Moreover, the ability to predict the CD34(+) cell yield permits improved management of the leukapheresis collection, with the only disadvantage of larger leukapheresis volume and higher hematocrit.     

冠心病与ABO血型的相关性研究

目的 研究冠心病(CHD)与ABO血型分布的关系.方法 选择我院2006-2010年冠心病患者3831例,采用血型群体分布方法,按年龄、性别等分组,进行ABO血型相关性分布的统计分析.结果 ASO血型分布在冠心病患者和对照组中存在显著性差异:A型x2=0.31(P>0.05),B型x2=15.72(P<0.01),O型x2=37.48(P<0.01),AB型x2=9.10(P<0.01),且其RR值分别为1.01、1.10、0.86、1.16.结论 冠心病患者与普通人群ABO血型分布存在显著性差异,其中B型和AB型为冠心病的危险因子,O型为冠心病保护因子.     

Evaluation of a new cell separator for collection of peripheral blood CD34+ progenitor cells in pediatric patients

BACKGROUND: This study was conducted to evaluate the performance of the COM.TEC cell separator (Fresenius HemoCare GmbH) for collecting CD34+ cells in pediatric patients who were intended to have autologous peripheral blood progenitor cell transplantation, with respect to collection variables, prediction power of CD34+ cell yield, and influence on donors. STUDY DESIGN AND METHODS: A total of 26 pediatric solid tumor patients who received mobilization chemotherapy and granulocyte–colony‐stimulating factor underwent CD34+ cell collection (n = 96) using the COM.TEC auto mononuclear cell (MNC) program. Patients were divided into a neuroblastoma (NBL) group and a brain tumor group according to the intensity of prior chemotherapy regimens. The collection variables, cellular variables of leukapheresis products, and the peripheral blood cell counts of patients were compared with those acquired using the COBE Spectra (GambroBCT). The CD34+ cell collection efficiency (CE) and the percentage ratios of actual to predicted CD34+ cell yield indicating prediction power were analyzed. RESULTS: Using the COM.TEC auto MNC program, the processing rate was higher and the product volume was smaller (p < 0.05) than those of the COBE Spectra. Platelet (PLT) reduction in peripheral blood and PLT contamination of the products were significantly lower (p < 0.01). The median CE was less than 60% in both patient groups (50.0 and 48.4%, respectively). The actual collected CD34+ cell yields were medians of 66.9 and 76.1% of the predicted values in NBL group and brain tumor group, respectively. CONCLUSION: PBPC collections by the COM.TEC cell separator had advantages of high processing rate, low product volume, and low contamination by PLTs of product. Low PLT loss was observed in pediatric patients who need to collect autologous PBPCs. However, applying CD34+ cell yield prediction was not practical for prospective scheduling of the next collection. More specified data need to be accumulated for more accurate prediction of CD34+ cell yield in pediatric patients.